Positron Emission Tomography in Diagnosis of Visual Variant Alzheimer Disease
J Neuro-Ophthalmol 29:149-150, Finelli,P.F., 2009
Callosal Atrophy with Reduced Cortical Oxygen Metabolism in Carotid Artery Disease
Stroke 24:88-93, Yamauchi,H.,et al, 1993
Borderzone Ischemia
Ann Neurol 22:707-713, Leblanc,R.,et al, 1987
FDG-PET/CT of Giant Cell Arteritis with Normal Inflammatory Markers
Ann Neurol 92:337-339, Koizumi, N.,et al, 2022
Role of Brain Imaging in Early Parkinsonism
BMJ 324:d638, Breen,D.P.,et al, 2011
Screening for tumours in paraneoplastic syndromes: report of an EFNS Task Force
Eur J Neurol 18:19-27, Titulaer, M.J.,et al, 2011
Pediatric Moyamoya Disease: An Analysis of 410 Consecutive Cases
Ann Neurol 68:92-101, Kim,S.-K., et al, 2010
Transplantation of Embryonic Dopamine Neurons for Severe Parkinson's Disease
NEJM 344:710-719,763, Freed,C.R.,et al, 2001
Ischemic Core and Penumbra in Human Stroke
Stroke 30:93-99, Kaufmann,A.M.,et al, 1999
Imaging the Brain, Part 1 & 2
NEJM 338:812-820, 889-8961998., Gilman,S., 1998
Clinical/Metabolic Correlations in Multiple System Atrophy, A PET Study
Arch Neurol 52:179-185, Perani,D.,et al, 1995
Neurological Sequelae of Cyanide Intoxication-The Patterns of Clinical MRI & Pet Findings
Ann Neurol 38:825-828, Rosenow,F.,et al, 1995
Complementary Positron Emission Tomographic Studies of the Striatal Dopaminergic System in Parkinson's Disease
Arch Neurol 52:1183-1190, Antonini,A.,et al, 1995
Early Differential Diagnosis of Parkinson's Disease with F-flurodeoxyglucose and Positron Emission Tomography
Neurol 45:1995-2004, Eidelberg,D.,et al, 1995
Clinical and[18F]dopa PET Findings in Early Parkinson's Disease
JNNP 59:597-600, Morrish,P.K.,et al, 1995
PET Imaging of the Dopamine Transporter with 11C-WIN 35, 428 Reveals Marked Declines in Mild Parkinson's Disease
Ann Neurol 34:423-431, Frost,J.J.,et al, 1993
New Anatomical and Functional Imaging Methods
Ann Neurol 32:395-400, Prichard,J.W.&Brass,L.M., 1992
Preclinical Detection of Parkinson's Disease
Neurology Suppl 2, 41:5-921991., Koller,W.C.&Langston,J.W., 1991
Cerebral Glucose Metabolism in the Course of Subacute Sclerosing Panencephalitis
Arch Neurol 46:97-100, Huber,M.,et al, 1989
An 80-Year-Old Woman with a Homonymous Hemianopsia
Neurol 99:713-717, Tajfirouz, D.,et al, 2022
EULAR Recommendations for the Use of Imaging in Large Vessel Vasculitis in Clinical Practice
Ann Rheum Dis 77:636-643, Dejaco,C.,et al, 2018
Prevalence of Cerebral Amyloid Pathology in Persons without Dementia
JAMA 313-1924-1938,1913, Jansen, W.J.,et al, 2015
Prevalence of Amyloid PET Positivity in Dementia Syndromes
JAMA 313:1939-1949,1913, Ossenkoppele, R.,et al, 2015
PET Imaging for Alzheimer Disease: Are Its Benefits Worth the Cost?
JAMA 309:1099-1100, Mitka, M., 2013
Cortical and Cerebellar Hypometabolism After Bilateral Antero-Inferior Cerebellar Artery Infarct
Neurol 78:69-70, Ayrignac, X.,et al, 2012
�-Amyloid Burden in Healthy Aging
Neurol 78:387-395, Rodrigue,K.M.,et al, 2012
Subjective Cognition and Amyloid Deposition Imaging
Arch Neurol 69:223-229, Perrotin,A.,et al, 2012
Predicting sites of New Hemorrhage with Amyloid Imaging in Cerebral Amyloid Angiopathy
Neurol 79:320-326, Gurol, M.E.,et al, 2012
Brain Amyloid Imaging - FDA Approval of Florbetapir F18 Injection
NEJM 367:885-887, Yang, L.,et al, 2012
Longitudinal Assessment of A-beta and Cognition in Aging and Alzheimer Disease
Ann Neurol 69:181-192, Villemagne,V.L.,et al, 2011
Changing Concepts of Alzheimer Disease
JAMA 35:2458-2459, McKhann, G.M., 2011
Treat Alzheimer Disease Before It Is Symptomatic
Arch Neurol 68:1237-1238, , 2011
Longitudinal Change of Biomakers in Cognitive Decline
Arch Neurol 68:1257-1266,1237, Lo, R.Y.,et al, 2011
In Vivo Mapping of Amyloid Toxicity in Alzheimer Disease
Neurol 72:1504-1511, Frisoni,B.G.,et al, 2009
Conversion of Amyloid Positive and Negative MCI to AD over 3 Years: An 11C-PIB PET Study
Neurol 73:754-760, 744, Okello,A.,et al, 2009
Pittsburg Compound B Imaging and Prediction of Progression From Cognitive Normality to Symptomatic Alzheimer Disease
Arch Neurol 66:1469-1475, Morris,J.,et al, 2009
Assessment of �-Amyloid in a Frontal Cortical Brain Biopsy Specimen and by Positron Emission Tomography with Carbon 11-Labeled Pittsburgh Compound B
Arch Neurol 65:1304-1309,1281, Leinonen,V.,et al, 2008
Frequent Amyloid Deposition Without Significant Cognitive Impairment Among the Elderly
Arch Neurol 65:1509-1517, Aizenstein,H.J.,et al, 2008
Imaging of Amyloid Burden and Distribution in Cerebral Amyloid Angiopathy
Ann Neurol 62:229-234, Johnson,K.A.,et al, 2007
Multiple Diagnostic Tests Are Needed to Assess Multiple Causes of Dementia
Arch Neurol 63:144-146,146, Rikkert,M.G.M.O.,et al, 2006
PET of Brain Amyloid and Tau in Mild Cognitive Impairment
NEJM 355:2652-2663, Small,G.W.,et al, 2006
Neuroimaging and Early Diagnosis of Alzheimer Disease: A Look to the Future
Radiology 226:315-336, Petrella,J.R.,et al, 2003
The Topography of Metabolic Deficits in Posterior Cortical Atrophy (the Visual Variant of Alzheimers Disease) with FDG-PET
JNNP 74:1521-1529, Nestor,P.J.,et al, 2003
Spontaneous Neurological Recovery After Stroke and the Fate of the Ischemic Penumbra
Ann Neurol 40:216-226, Furlan,M.,et al, 1996
Dementia in Down's Syndrome:Cerebral Glucose Utilization, Neuropsychological Assessment, and Neuropathology
Neurol 38:938-942, Schapiro,M.B.,et al, 1988
Alzheimer's Disease
NEJM 314:964-973, Katzman,R., 1986